Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 


Bioresorbable Vascular Scaffold now available in New Zealand

World’s first Bioresorbable Vascular Scaffold now available to New Zealanders

New Zealand played key role in the development of Absorb™ - an innovative,

new device for the treatment of coronary artery disease

AUCKLAND, New Zealand, 17 October 2012 – Absorb, the world’s first drug eluting bioresorbable vascular scaffold for the treatment of coronary artery disease is now widely available in New Zealand. Abbott’s Absorb is an innovative device that is designed to open a blocked heart vessel, restore blood flow to the heart and then, unlike permanent metallic stents, dissolve into the body. This leaves patients with a vessel free of a metallic stent, which can result in long-term benefits.

New Zealand played a key role in the development of this innovative new treatment. The first person in the world to be treated with Absorb as part of a clinical trial in 2006 was John Lamb from Tauranga, New Zealand.

“Unlike metallic stents, Absorb dissolves away after doing its job,” said John Ormiston, M.D., Medical Director at Mercy Angiography in Auckland and Principal Investigator in one of the pivotal Absorb trials. “This is a significant advancement in the treatment of coronary artery disease, as the treated vessel has the potential to return to a more natural state. It may be free to move, flex and dilate similar to a natural vessel in response to normal activity, such as exercise. This makes Absorb a true innovation for patients.”

Absorb is made of polylactide, a proven, biocompatible material that is used in medical implants such as dissolvable sutures. The device is designed to slowly metabolise and eventually break down into elements that occur naturally in the body.

The long-term benefits of a therapy like Absorb are significant. “In addition to the potential to restore natural vessel function in a way not possible with permanent implants, a temporary scaffold could allow more complete healing of the vessel, potentially reducing the need for long-term anti-clotting medications.” said Dougal McClean, M.D., Interventional Cardiologist and Director of Interventional Research at Christchurch Hospital.


The Absorb technology further increases future treatment and diagnostic options, especially in younger patients, but also potentially in people with early disease who are at high risk.

On average, one New Zealander dies of coronary artery disease every 90 minutes and one in twenty adults have been diagnosed with the disease.1 Coronary artery disease is a condition in which the arteries that supply blood to the heart become narrowed or blocked by a build-up of plaque. Plaque is made up of fat, cholesterol or other fatty deposits that accumulate on the inner wall of the artery.

“The knowledge that with Absorb you don’t have a permanent metallic stent left in your body once the device has done its job really appeals to me,” said John Lamb, patient from Tauranga who received Absorb in 2006.

About the Absorb Bioresorbable Vascular Scaffold

The Absorb bioresorbable vascular scaffold, made by global health care company Abbott, is the first drug eluting device of its kind for the treatment of coronary artery disease. Absorb is designed to open a blocked vessel and to restore blood flow to the heart. The scaffold, similar to a mesh tube, provides support until the artery can stay open on its own and then dissolves. Because a permanent metallic stent is not left behind, naturally occurring vessel functions may be restored, which is one of the features that makes this device a significant innovation for patients in the treatment of coronary artery disease.

Abbott's Absorb delivers everolimus, an anti-proliferative drug used in Abbott's XIENCE coronary stent systems. Everolimus was developed by Novartis Pharma AG and is licensed to Abbott by Novartis for use on its drug eluting vascular devices. Everolimus has been shown to inhibit in-stent neointimal growth in the coronary vessels following stent implantation, due to its anti-proliferative properties.

ends

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

Must Sell 20 Petrol Stations: Z Cleared To Buy Caltex Assets

Z Energy is allowed to buy the Caltex and Challenge! petrol station chains but must sell 19 of its retail sites and one truck-stop, the Commerce Commission has ruled in a split decision that acknowledges possible retail price coordination between fuel retailers occurs in some regions. More>>

ALSO:

Huntly: Genesis Extends Life Of Coal-Fuelled Power Station To 2022

Genesis Energy will keep its two coal and gas-fired units at Huntly Power Station operating until 2022, having previously said they'd be closed by 2018, after wringing a high price from other electricity generators who wanted to keep them as back-up. More>>

ALSO:

Dammed If You Do: Ruataniwha Irrigation Scheme Hits Farmer Uptake Targets

Enough Hawke's Bay farmers have signed up for water from the proposed Ruataniwha Water Storage Scheme for it to go ahead as long as a cornerstone institutional capital investor can be found to back it, its regional council promoter announced. More>>

ALSO:

Reserve Bank: OCR Stays At 2.25%

Reserve Bank governor Graeme Wheeler kept the official cash rate at 2.25 percent, in a decision traders had said could go either way, while predicting inflation will pick up as the slump in oil prices washes out of the data and capacity pressures start to build in the economy. More>>

ALSO:

Export Values Down: NZ Posts Biggest Annual Trade Deficit In 7 Years

New Zealand has recorded its biggest annual trade deficit since April 2009, reflecting weaker prices of agricultural commodities such as dairy products, beef and lamb, and increased imports of vehicles and machinery. More>>

ALSO:

Currency Events: NZ's New $5 Note Wins International Banknote Award

New Zealand’s new Brighter Money $5 note has been named Banknote of the Year in a prestigious international competition. The $5 note was awarded the IBNS Banknote of the Year title at the International Bank Note Society’s annual meeting. More>>

ALSO:

Get More From Scoop

 
 
 
 
 
 
 
 
 
Sci-Tech
Search Scoop  
 
 
Powered by Vodafone
NZ independent news